SCHEMBL9607828

SCHEMBL9607828

CCC(C)/C=C/C(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17183721 1.00
SCHEMBL3230819 0.82 ALDH1A1 (0.36)
SCHEMBL7610787 0.81
SCHEMBL17183781 0.79 SLC7A5 (0.38)
SCHEMBL15711115 0.79 MCL1 (0.33)
SCHEMBL11473461 0.79 CA2 (0.44)
SCHEMBL26965736 0.79 TDP1 (0.32)
SCHEMBL6722055 0.78
SCHEMBL6717535 0.78
SCHEMBL20356933 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242171-B2 Method for reducing the weight of a subject or inhibiting weight gain in a subject PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-08-14 US disclosed
US-20120135091-A1 METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES US ARMY, SECRETARY OF THE ARMY 2012-05-31 US disclosed
US-20120029065-A1 COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) 2012-02-02 US disclosed
US-8017634-B2 Compositions for treating obesity and insulin resistance disorders PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-09-13 US disclosed
US-20100316679-A1 COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-12-16 US disclosed
US-20080194803-A1 Cognitive Performance With Sirtuin Activators HOWARD HUGHES MEDICAL INSTITUTE 2008-08-14 US disclosed
US-20070149466-A1 Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders SIRTRIS PHARMACEUTICALS, INC. 2007-06-28 US disclosed
US-20070014833-A1 Treatment of eye disorders with sirtuin modulators SIRTRIS PHARMACEUTICALS, INC. (US) 2007-01-18 US disclosed